Tagraxofusp

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Blastic plasmacytoid dendritic cell neoplasm, in adults and paediatric patients 2 years... (FDA)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Weak signal

Also approved (2)
US
  • Blastic plasmacytoid dendritic cell neoplasm, in adults and paediatric patients 2 years and older
Product first approved 2018Outside this platform's coverageFDA label
EU
  • Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Product first approved 2021Outside this platform's coverageEMA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (7)
Acute Myeloid Leukemia
NCT05442216 · Joshua Zeidner
2024-05-01 – 2031-07-21 · Acute Myeloid Leukemia
What this study did
NCT07949370 · Dana-Farber Cancer Institute
2027-03-06 – 2030-07-31 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT04342962 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2021-02-16 – 2024-01-18 · Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07007052 · French Innovative Leukemia Organisation
2025-12-11 – 2031-10-02 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
What this study did
NCT04216524 · M.D. Anderson Cancer Center
2020-05-29 – 2026-12-31 · Blastic Plasmacytoid Dendritic Cell Neoplasm
What this study did
NCT04317781 · M.D. Anderson Cancer Center
2020-03-27 – 2023-07-11 · Blastic Plasmacytoid Dendritic Cell Neoplasm
What this study did
Phase 1/2 (9)
Acute Myeloid Leukemia
NCT07148180 · Jacqueline Garcia, MD
2026-02-02 – 2030-12-31 · Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
What this study did
NCT06561152 · Stanford University
2025-02-10 – 2028-10 · Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
What this study did
NCT02270463 · Stemline Therapeutics, Inc.
2015-02 – 2019-12 · Acute Myeloid Leukemia
What this study did
NCT00397579 · University of Texas Southwestern Medical Center
2013-05 – 2017-07-27 · Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
What this study did
Other / comorbidity
NCT05038592 · M.D. Anderson Cancer Center
2022-03-04 – 2027-01-29 · Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
What this study did
NCT05032183 · M.D. Anderson Cancer Center
2022-02-17 – 2024-07-31 · Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia
What this study did
NCT02268253 · Stemline Therapeutics, Inc.
2016-02-10 – 2023-03-27 · Myelofibrosis, Chronic Myelomonocytic Leukemia
What this study did
NCT02661022 · Stemline Therapeutics, Inc.
2016-01 – 2019-12 · Multiple Myeloma
What this study did
Phase 1 (7)
Acute Myeloid Leukemia
NCT05476770 · Therapeutic Advances in Childhood Leukemia Consortium
2022-11-11 – 2027-11-11 · Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
What this study did
NCT06498973 · City of Hope Medical Center
2025-01-28 – 2027-04-25 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT05233618 · Karen Ballen, MD
2022-07-13 – 2026-12-01 · Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
What this study did
NCT05720988 · Jonsson Comprehensive Cancer Center
2024-08-03 – 2026-08-03 · Acute Myeloid Leukemia
What this study did
NCT05716009 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2023-11-20 – 2025-07-16 · Acute Myeloid Leukemia
What this study did
Other / comorbidity

Competitive landscape

5 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tagraxofusp: this drugPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
OrcaGraft (Orca-Q)Phase 1/2Cell therapyTreg-enriched allogeneic haematopoietic stem cell graftnot yet gradedNo reviewed efficacy summary in this indication
Allo-RevCAR01-TPhase 1Cell therapyCD123not yet gradedNo reviewed efficacy summary in this indication
BYON4413Phase 1Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
BexatamigDiscontinuedMultispecific antibodyCD123Weak signalFeatured results are dose-finding only in this race

Large race: only the 65 furthest-along competitors are listed; 65 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tagraxofusp to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Myelofibrosis,MFRecruiting
Est. primary completion 2026-12 · NCT06414681 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04216524 · CT.gov ↗
What to watch
2027 (3)
January 2027 (1)
Phase 1/2Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 …Active not recruiting
Est. primary completion 2027-01-29 · NCT05038592 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04-25 · NCT06498973 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10 · NCT06561152 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-02-09 · NCT06456463 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Recruiting
Est. primary completion 2028-12-10 · NCT07007052 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07148180 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07949370 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-07-21 · NCT05442216 · CT.gov ↗
What to watch

See the full readout calendar ↗